Table 3.
Detailed individual outcome of 15 patients that underwent further analysis in the current case series
| Patient No. | Preoperative |
Surgeon | Sling type | Postoperative |
PGI | VAS |
24-Hr pad test (g) | Follow-up (mo) | Cured | Improved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pads | IQoL | ICIQ-SF | Pads | IQoL | ICIQ-SF | Perineal | Inguinal | ||||||||
| 1a | 5 | NR | NR | A | AdVance | NR | NR | NR | NR | NR | NR | NR | NR | No | No |
| 2 | NR | 51.1 | 15 | A | AdVance | 0 | 90.9 | 5 | 1 | 1 | 0 | 0 | 83 | Yes | No |
| 3 | 4 | 31.8 | 21 | A | AdVance | 3 | 72.7 | 12 | 1 | 0 | 0 | 209 | 83 | No | Yes |
| 4a | 6 | 15.9 | 16 | A | AdVance | NR | NR | NR | NR | NR | NR | NR | NR | No | No |
| 5 | 5 | NR | NR | A | AdVance | 0 | 36.4 | 7 | 2 | 0 | 0 | 0 | 79 | Yes | No |
| 6 | 4 | 30.7 | 16 | A | AdVance | 3 | 45.5 | 13 | 4 | 0 | 0 | 20 | 80 | No | Yes |
| 7 | 5 | NR | 15 | A | AdVance | 3 | 85.2 | 13 | 4 | 0 | 0 | 130 | 64 | No | No |
| 8 | 7 | 15.9 | 16 | A | AdVance | 2 | 51.1 | 13 | 3 | 1 | 0 | 40 | 72 | No | Yes |
| 9 | 2 | 51.1 | 14 | A | AdVance | 1 SP | 68.2 | 8 | 2 | 1 | 1 | 4 | 70 | Yes | No |
| 10 | NR | NR | 12 | A | AdVance | 0 | 90.9 | 4 | 1 | 0 | 0 | 0 | 70 | Yes | No |
| 11 | 6 | NR | 14 | B | AdVance | 5 | 8 | 20 | 6 | 2 | 2 | 0 | 62 | No | No |
| 12 | 5 | 68.2 | 4 | B | AdVanceXP | 6 | 18.2 | 21 | 1 | 0 | 0 | 0 | 51 | No | No |
| 13 | 4 | 31.8 | 15 | B | AdVanceXP | 0 | 100 | 0 | 1 | 0 | 0 | 0 | 38 | Yes | No |
| 14 | 4 | 45.5 | 14 | B | AdVanceXP | 0 | 100 | 0 | 1 | 0 | 0 | 0 | 34 | Yes | No |
| 15 | 2 | 30.7 | 15 | B | AdVanceXP | 0 | 95.5 | 8 | 2 | 0 | 0 | 2 | 18 | Yes | No |
Note that patient 1 and 4 underwent implantation of an artificial urinary sphincter during follow-up period.
ICIQ-SF, International Consultation on Incontinence Questionnaire Short Form; IQoL, International Quality of Life score; NR, not reported; PGI, patient’s global impression of improvement score; SP, safety pad; VAS, visual analogue scale.